Board of Directors
The Kypha board of directors have been selected to provide leadership, industry experience, expertise and guidance to the company. Each board member has an established track record in their own industry as well as been involved in the leadership and ownership life cycle of start-up companies.
James D. Merselis
Chairman of the Board
James D. Merselis joined the board of Trinity Biotech (NASDAQ-GS:TRIB) in February 2009 as a non-executive director. He is a Director of Biosensia Ltd; a pre-commercial, point-of-care diagnostics company located in Dublin, Ireland. In addition, he is Chairman of Abram Scientific Inc., point-of-care, coagulation monitoring company located in California.
David Smoller, PhD
Prior to joining Horizon Discovery as their Chief Business officer. David was CEO of Sage Labs. Sage Labs was a life science company developing genetically modified Rodents using gene editing technologies. Sage was acquired in 2014 by Horizon Discovery.
Chad Stiening, PhD
Director, CEO/Founder of Kypha
Co-Founder of Kypha and the driving force behind the team’s innovative approach to the next big thing in inflammation diagnostics. A visionary leader with a passion for entrepreneurship and technology commercialization, and a strong track record for attracting resources, advisors, and a talented team to propel Kypha forward in the inflammation diagnostics marketplace.
Jonathan Sackier, MD, MB, ChB, FRCS, FACS
Jonathan M. Sackier, MD, MB, ChB, FRCS, FACS, trained as a surgeon in the United Kingdom and developed and brought to market a number of healthcare innovations. He consults to health care companies, sits on several corporate and scientific advisory boards and is a visiting professor at Oxford University’s Nuffield Department of Surgical Sciences.
Manager, Arsenal Capital Management, LLC
Peter Reinecke is the founder and managing director of Arsenal Capital Management, LLC (ACM). ACM was founded in December 2012 and began operations in February 2013.
Andrew T. Hoyne
Andrew practices business and corporate law focused upon the representation of life sciences and other technology-based companies. His clients include/have included multi-billion dollar corporations, Big Ten universities, emerging companies and investors. Andy’s life science practice includes pharmaceuticals, medical devices, research services, chemical and biochemical products, agriculture, and bio-energy clients.